459.62
2.59 (0.57%)
| Previous Close | 457.03 |
| Open | 458.45 |
| Volume | 763,957 |
| Avg. Volume (3M) | 1,679,734 |
| Market Cap | 118,029,033,472 |
| Price / Earnings (Forward) | 20.20 |
| Price / Sales | 8.93 |
| Price / Book | 5.89 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -8.91% |
| Operating Margin (TTM) | 37.22% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | 3.00% |
| Quarterly Earnings Growth (YOY) | -41.20% |
| Total Debt/Equity (MRQ) | 10.00% |
| Current Ratio (MRQ) | 2.65 |
| Operating Cash Flow (TTM) | -980.30 M |
| Levered Free Cash Flow (TTM) | 2.63 B |
| Return on Assets (TTM) | 11.77% |
| Return on Equity (TTM) | -5.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vertex Pharmaceuticals Incorpor | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 97.64% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 553.00 (UBS, 20.32%) | Buy |
| Median | 476.50 (3.67%) | |
| Low | 405.00 (RBC Capital, -11.88%) | Hold |
| Average | 477.29 (3.84%) | |
| Total | 9 Buy, 5 Hold | |
| Avg. Price @ Call | 385.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 11 Sep 2025 | 475.00 (3.35%) | Buy | 397.37 |
| Canaccord Genuity | 06 Aug 2025 | 411.00 (-10.58%) | Hold | 385.65 |
| Guggenheim | 06 Aug 2025 | 546.00 (18.79%) | Buy | 385.65 |
| Wells Fargo | 06 Aug 2025 | 460.00 (0.08%) | Buy | 385.65 |
| BMO Capital | 05 Aug 2025 | 530.00 (15.31%) | Buy | 374.98 |
| Cantor Fitzgerald | 05 Aug 2025 | 485.00 (5.52%) | Buy | 374.98 |
| HC Wainwright & Co. | 05 Aug 2025 | 478.00 (4.00%) | Buy | 374.98 |
| 23 Jun 2025 | 550.00 (19.66%) | Buy | 443.54 | |
| Morgan Stanley | 05 Aug 2025 | 439.00 (-4.49%) | Hold | 374.98 |
| 20 Jun 2025 | 460.00 (0.08%) | Hold | 440.87 | |
| RBC Capital | 05 Aug 2025 | 405.00 (-11.88%) | Hold | 374.98 |
| 17 Jun 2025 | 420.00 (-8.62%) | Hold | 441.99 | |
| Scotiabank | 05 Aug 2025 | 438.00 (-4.70%) | Hold | 374.98 |
| Stifel | 05 Aug 2025 | 455.00 (-1.01%) | Hold | 374.98 |
| Truist Securities | 05 Aug 2025 | 490.00 (6.61%) | Buy | 374.98 |
| UBS | 05 Aug 2025 | 553.00 (20.32%) | Buy | 374.98 |
| JP Morgan | 14 Jul 2025 | 517.00 (12.48%) | Buy | 472.35 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |